Pila Pharma

<p>Pila Pharma today announced satisfactory results in terms of side effects in the 13-week tox study. Outstanding investigations regarding pathology, bioanalysis, and toxicokinetic analyses, are yet to be completed, and the company expects the complete data package to be acquired in early 2023. This data package is required to advance XEN-DIA to the phase llb-trial expected to commence in 2023 (we assume H2).</p>
<p>We feel encouraged for the investment case that the preparations of  XEN-DIA ahead of the crucial phase llb-trial are progressing according to plan. However, we once again state that the financing situation is a hurdle and the most urgent event ahead of the company. We assume that investors will learn more on this topic in connection to the Q3 report.</p>
